Abstract
Narcolepsy is a debilitating sleep disorder with excessive daytime sleepiness and cataplexy as its two major symptoms. Although this disease was first described about one century ago, an animal model was not available until the 1970s. With the establishment of the Stanford canine narcolepsy colony, researchers were able to conduct multiple neurochemical studies to explore the pathophysiology of this disease. It was concluded that there was an imbalance between monoaminergic and cholinergic systems in canine narcolepsy. In 1999, two independent studies revealed that orexin neurotransmission deficiency was pivotal to the development of narcolepsy with cataplexy. This scientific leap fueled the generation of several genetically engineered mouse and rat models of narcolepsy. To facilitate further research, it is imperative that researchers reach a consensus concerning the evaluation of narcoleptic behavioral and EEG phenomenology in these models.
Keywords: Narcolepsy, Cataplexy, Sleep, EEG, Animal model, Rodent, Canine, REM
CNS & Neurological Disorders - Drug Targets
Title: Animal Models of Narcolepsy
Volume: 8 Issue: 4
Author(s): Lichao Chen, Ritchie E. Brown, James T. McKenna and Robert W. McCarley
Affiliation:
Keywords: Narcolepsy, Cataplexy, Sleep, EEG, Animal model, Rodent, Canine, REM
Abstract: Narcolepsy is a debilitating sleep disorder with excessive daytime sleepiness and cataplexy as its two major symptoms. Although this disease was first described about one century ago, an animal model was not available until the 1970s. With the establishment of the Stanford canine narcolepsy colony, researchers were able to conduct multiple neurochemical studies to explore the pathophysiology of this disease. It was concluded that there was an imbalance between monoaminergic and cholinergic systems in canine narcolepsy. In 1999, two independent studies revealed that orexin neurotransmission deficiency was pivotal to the development of narcolepsy with cataplexy. This scientific leap fueled the generation of several genetically engineered mouse and rat models of narcolepsy. To facilitate further research, it is imperative that researchers reach a consensus concerning the evaluation of narcoleptic behavioral and EEG phenomenology in these models.
Export Options
About this article
Cite this article as:
Chen Lichao, Brown E. Ritchie, McKenna T. James and McCarley W. Robert, Animal Models of Narcolepsy, CNS & Neurological Disorders - Drug Targets 2009; 8 (4) . https://dx.doi.org/10.2174/187152709788921717
DOI https://dx.doi.org/10.2174/187152709788921717 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Insights into Anti-Trypanosomal Agents Based on Synthetic Glycoconjugates
Current Topics in Medicinal Chemistry Autonomic Nervous System Alterations in Rett Syndrome
Current Pediatric Reviews Alzheimer’s Disease and Autistic Spectrum Disorder: Is there any Association?
CNS & Neurological Disorders - Drug Targets GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Cortical Auditory Dysfunction in Childhood Epilepsy: Electrophysiologic Evidence
Current Pediatric Reviews Histamine H3 Receptor Ligands in the Group of (Homo)piperazine Derivatives
Current Medicinal Chemistry Concerns with AED Conversion: Comparison of Patient and Physician Perspectives
Current Neuropharmacology Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs
Current Drug Metabolism Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry Neuropharmacological Profile of Gamma-Decanolactone on Chemically-induced Seizure in Mice
Central Nervous System Agents in Medicinal Chemistry Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued) Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Current Medicinal Chemistry Amygdalar Atrophy in Early Alzheimer’s Disease
Current Alzheimer Research Synaptic Plasticity, Metaplasticity and Depression
Current Neuropharmacology Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients
Current Rheumatology Reviews